Cagrilintide.
C💡 Explain this simply
Cagrilintide is an investigational compound in the glp-1 & incretin receptor agonists.
It draws interest for glp-1 & incretin receptor agonists.
C-tier evidence: some human evidence exists but isn't definitive.
General anti-aging / longevity; Human injury recovery; Muscle growth or fat loss claims.
Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.
Before you decide, compare Cagrilintide with Semaglutide, Liraglutide, Tirzepatide. See all →
Cagrilintide is an investigational compound in the glp-1 & incretin receptor agonists.
Its biological effect is described in the mechanism section.
It draws interest for glp-1 & incretin receptor agonists.
C-tier evidence: some human evidence exists but isn't definitive.
A long-acting amylin analogue (Novo Nordisk) for weight management. A randomized, placebo- and active-controlled phase-2 dose-finding trial showed significant, dose-dependent weight reduction with good tolerability — real human evidence, still pre-approval.
Verified citations resolve to PubMed / FDA. See how we score.
Cagrilintide: the research file
What it is
Cagrilintide (development code AM833) is a long-acting, once-weekly synthetic analogue of the pancreatic hormone amylin, developed by Novo Nordisk. It is a "dual amylin and calcitonin receptor agonist" (DACRA)-class peptide engineered with a lipidation (fatty-acid acylation) that prolongs its half-life, and is being investigated for chronic weight management in adults with overweight or obesity, both as a monotherapy and as the amylin component of the fixed-dose combination CagriSema (with semaglutide).
How it works
Native amylin is co-secreted with insulin from pancreatic beta cells and reduces food intake by promoting meal-ending satiety, slowing gastric emptying, and suppressing glucagon. Cagrilintide mimics this by activating amylin and calcitonin receptors, which are heterodimers of the calcitonin receptor with receptor-activity-modifying proteins (RAMPs). Preclinical work in RAMP1/RAMP3 knockout mice (eBioMedicine, 2025) indicates cagrilintide's weight-lowering effect is mediated largely through brain amylin receptors 1 and 3 in hindbrain and hypothalamic circuits that govern appetite. Because amylin signaling is mechanistically distinct from GLP-1, combining the two (as in CagriSema) is intended to engage complementary satiety pathways and produce additive weight loss.
What the evidence shows
Human data are now substantial for the combination and growing for monotherapy. The pivotal phase 3 REDEFINE 1 trial in over 3,400 adults with overweight/obesity without diabetes (NEJM 2025, PMID 40544433) reported mean weight loss of roughly 20.4% with CagriSema, 11.8% with cagrilintide monotherapy, 14.9% with semaglutide, and about 3% with placebo at 68 weeks; cagrilintide thus produced clinically meaningful weight loss on its own, though less than the combination. REDEFINE 2 studied CagriSema in type 2 diabetes, and additional REDEFINE/REIMAGINE program trials (e.g., REIMAGINE 2 in The Lancet Diabetes & Endocrinology, 2026) extend the dataset. The brain-receptor mechanism evidence (eBioMedicine, PMID 40609154) is preclinical (mouse), so the molecular target attribution should not be read as proven in humans; most large efficacy data describe the semaglutide combination rather than cagrilintide alone.
Safety considerations
In the REDEFINE program the safety profile of cagrilintide and CagriSema was reported as broadly consistent with incretin/amylin-based therapies, with predominantly mild-to-moderate gastrointestinal effects (nausea, vomiting, diarrhea, constipation) as the most common adverse events, generally most pronounced during dose escalation. Long-term safety, cardiovascular outcomes, and the safety of cagrilintide as a standalone therapy are not yet fully characterized in published phase 3 data, and head-to-head long-term comparisons remain limited. As an investigational agent, cagrilintide has no established safety profile for use outside of controlled clinical trials; material sold as research-only "cagrilintide" is not a regulated medicine and carries unknown identity, purity, and contamination risks.
Regulatory status
Cagrilintide is investigational and not approved by the FDA as a standalone drug. Novo Nordisk submitted an NDA for the CagriSema combination (cagrilintide plus semaglutide) for weight management on December 18, 2025; as of mid-2026 it remains under FDA review and is not yet approved.
- Long-acting (once-weekly), lipidated amylin analogue; Novo Nordisk code AM833
- Belongs to the dual amylin and calcitonin receptor agonist (DACRA) class
- Is the amylin half of CagriSema, paired with the GLP-1 agonist semaglutide
- Phase 3 REDEFINE 1 (NEJM 2025): ~11.8% mean weight loss as monotherapy vs ~20.4% for the combination at 68 weeks
- Mechanism attributed to brain amylin receptors 1 and 3 in preclinical mouse studies
- CagriSema NDA filed Dec 2025; not FDA-approved as of mid-2026
- [1]Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) — New England Journal of Medicine, 2025, PMID 40544433
- [2]Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 — EBioMedicine, 2025, PMID 40609154 (preclinical, mouse)
- [3]Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2) — The Lancet Diabetes & Endocrinology, 2026, PMID 42251859
- [4]Novo Nordisk files for FDA approval of CagriSema (NDA submission announcement) — Novo Nordisk company announcement, December 18, 2025
Currently sits at Clinical trials — Studied in human clinical trials; evidence is meaningful.
Jargon, decoded: · · ·
Areas this compound is studied or discussed for — not guaranteed effects.
- Cagrilintide is a long-acting amylin analog — amylin is a hormone co-secreted with insulin that affects satiety and gastric emptying.
- It is investigational and studied for weight management, notably combined with semaglutide (the CagriSema program).
- Investigational; not FDA-approved.
- Efficacy and safety are still being established in trials.
Marketing claim vs what the data actually shows. Tap a row for detail.
Claim audit for Cagrilintide is in progress — common claims will be checked against sources here. Meanwhile, the real source corpus is in References.
Stack fit
Decision clarity: MediumPromising evidence, but with gaps in human data, safety, or approval.
Stack verdict: Interesting on paper, but not a clinically proven option. The internet narrative is stronger than the human evidence.
Cagrilintide is not established for:
Tier ranking
A weighted evidence score of 53/100 places cagrilintide in C tier — based on published evidence, not popularity.
Weighted evidence score 53/100
Why not B: held back by regulatory clarity.
Why not D: supported by its overall evidence profile.
What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.
What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.
- Cagrilintide is not FDA-approved for human use; it is discussed in a research context.
- It belongs to the GLP-1 & incretin receptor agonists class.
- Whether observed effects reliably translate to humans at large.
- Long-term safety in healthy users, and full drug-interaction risk.
- Optimal studied parameters outside any approved indication.
- Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
- Quality and purity of material from non-pharmaceutical sources.
This is not medical advice. These are areas where professional guidance and better evidence matter most.
See it next to its closest alternatives.
Full brief
A deeper, chapter-by-chapter research briefing. Tap any chapter to expand.
- What it is
- The preclinical evidence lane
- Why Early, and not higher or lower
- Proven lane vs speculative lane
- What people report
- Regulatory status
- What changed recently
01What it is
Simple takeaway: Cagrilintide is a research compound in the glp-1 & incretin receptor agonists.
Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists. It is not approved for human use; it is discussed here in a research context only.
03The preclinical evidence lane
Simple takeaway: Support is mainly preclinical; 0 registered trials and 0 sources indexed.
The most defensible evidence comes from animal and mechanistic models. Human clinical evidence is present but limited.
04Why Early, and not higher or lower
Simple takeaway: Composite maturity 2.8/5.
What holds it back: regulatory clarity. What supports its placement: its overall evidence profile. Stronger human trials, clearer long-term safety data, and regulatory progress would move it up; a safety signal or failure to replicate would move it down.
05Proven lane vs speculative lane
Simple takeaway: The research interest is real; most popular claims remain speculative.
What's supported is the preclinical/mechanistic research. What's speculative is the broad human benefit frequently claimed online, which the indexed human evidence does not establish.
06What people report
Simple takeaway: Community reports are not clinical evidence.
Online reports can surface expectation patterns and possible safety signals, but they are shaped by placebo effects, selection bias, confounders, and uncertain product quality and sourcing. We don't treat anecdotes as proof and we don't publish dosing or protocols.
07Regulatory status
Simple takeaway: Investigational
In clinical development; not approved. Regulatory status can change and differs by country; several peptides are also prohibited in sport (WADA). Verify current status before relying on it.
08What changed recently
Simple takeaway: No major evidence-changing update was identified in this review window.
The current profile reflects the existing body of indexed evidence. Material changes — new trials, approvals, or safety findings — are noted here when an editor logs them.
How the community sees this vs the evidence.
Evidence tier is C. Do you agree?
Community votes reflect user perception, not scientific proof — the evidence tier comes from our Research Maturity Index. Aggregate community sentiment will appear here once enough votes are collected.
Aggregate community sentiment will appear here once enough votes are in — we don't show invented numbers.
Get notified when new studies, safety updates, regulatory changes, or the tier ranking change.
FAQs
Is Cagrilintide FDA-approved?
No. Cagrilintide is not FDA-approved for the uses commonly discussed online. In clinical development; not approved.
What is Cagrilintide studied for?
Cagrilintide is studied mainly for weight loss. Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists.
What does the research say about Cagrilintide?
Promising but early. Some human evidence exists, but it isn't yet definitive and gaps remain.
Is Cagrilintide safe?
Long-term human safety is not well established for Cagrilintide. Quality and purity from non-pharmaceutical sources is an added risk.
🧮 Reconstitution calculator (educational)
Educational reconstitution math from your own values — not medical advice or a dose recommendation. Open the full calculator →
Each unit on a 100u · 1.0 mL syringe ≈ 25 mcg of this solution.
Show the math
More water → lower concentration → more units for the same amount.
Get the vial, water, target, and 10-unit draw sent to your inbox so it's easy to reference — and follow when the evidence changes. Free, no account.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.